Ipamorelin Guide

Ipamorelin binds the growth hormone secretagogue receptor 1a on pituitary somatotrophs — the same receptor that ghrelin activates. This binding triggers a calcium-dependent signaling cascade that stimulates GH synthesis and pulsatile release from the pituitary gland. The key difference from ghrelin is that ipamorelin does not activate the parallel receptor pathways that drive hunger, cortisol, and prolactin release.

Ipamorelin's GH release is dramatically amplified when endogenous GHRH signaling is present or when an exogenous GHRH analogue (like CJC-1295) is co-administered. The GHSR-1a and GHRH receptor pathways are genuinely synergistic at the pituitary — both are needed simultaneously to produce a maximal GH pulse. This is the mechanistic basis for the CJC-1295 + ipamorelin stack being so much more effective than either alone.

Elevated GH from repeated ipamorelin pulses signals the liver to produce Insulin-like Growth Factor 1 (IGF-1), which mediates most of GH's anabolic and body composition effects. Regular ipamorelin use (2–3x daily) raises IGF-1 approximately 15–30% from baseline. When stacked with CJC-1295 DAC, the IGF-1 rise can exceed 50% — important context for monitoring and staying within physiologic reference ranges.

Unlike some peptides and GH secretagogues, ipamorelin shows no evidence of receptor desensitization at standard doses with ongoing use. This is mechanistically explained by its pulsatile delivery pattern — the receptor is not chronically occupied. Continuous GHSR-1a stimulation (as with some small molecule secretagogues) produces tachyphylaxis; pulsatile agonism as produced by ipamorelin injections does not.

GHSR-1a Agonism: Ipamorelin binds the growth hormone secretagogue receptor 1a on pituitary somatotrophs — the same receptor that ghrelin activates. This binding triggers a calcium-dependent signaling cascade that stimulates GH synthesis and pulsatile release from the pituitary gland. The key difference from ghrelin is that ipamorelin does not activate the parallel receptor pathways that drive hunger, cortisol, and prolactin release.

Synergy with Endogenous GHRH: Ipamorelin's GH release is dramatically amplified when endogenous GHRH signaling is present or when an exogenous GHRH analogue (like CJC-1295) is co-administered. The GHSR-1a and GHRH receptor pathways are genuinely synergistic at the pituitary — both are needed simultaneously to produce a maximal GH pulse. This is the mechanistic basis for the CJC-1295 + ipamorelin stack being so much more effective than either alone.

IGF-1 Downstream Response: Elevated GH from repeated ipamorelin pulses signals the liver to produce Insulin-like Growth Factor 1 (IGF-1), which mediates most of GH's anabolic and body composition effects. Regular ipamorelin use (2–3x daily) raises IGF-1 approximately 15–30% from baseline. When stacked with CJC-1295 DAC, the IGF-1 rise can exceed 50% — important context for monitoring and staying within physiologic reference ranges.

No Desensitization: Unlike some peptides and GH secretagogues, ipamorelin shows no evidence of receptor desensitization at standard doses with ongoing use. This is mechanistically explained by its pulsatile delivery pattern — the receptor is not chronically occupied. Continuous GHSR-1a stimulation (as with some small molecule secretagogues) produces tachyphylaxis; pulsatile agonism as produced by ipamorelin injections does not.